Company / R&D Expense
IRADIMED CORP R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$3.0M
FY2025
5-year range
$1.4M / $3.0M
FY2021-FY2025
Trend
+5.0%
vs FY2024
Sector context
#110 of 110
Health Care
What the data says
Among 110 Health Care companies, IRADIMED CORP is in the bottom 0% for r&d expense. R&D Expense has fluctuated over the past 10 years, ranging from $1M in FY2016 to $3M in FY2025.
Based on SEC 10-K filings.
$3M in FY2025 with a 5-year CAGR of +9.4%.
Improved from $3M to $3M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +16.0%
- 5-Year CAGR
- +9.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 0% in Health CareTop 100% of 110This company $3.0M Sector average $298.2M
▼
-99.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +9.4%, indicating consistent growth.
- In FY2025, r&d expense increased 5.0% year-over-year.
- Ranks #110 out of 110 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 5.29 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.0M | +5.0% |
| FY2024 | $2.8M | -0.9% |
| FY2023 | $2.9M | +50.1% |
| FY2022 | $1.9M | +33.0% |
| FY2021 | $1.4M | -24.7% |
| FY2020 | $1.9M | +32.8% |
| FY2019 | $1.4M | +6.3% |
| FY2018 | $1.3M | -23.6% |
| FY2017 | $1.8M | +65.1% |
| FY2016 | $1.1M | +0.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026